T. Rowe Price Associates’s Burning Rock Biotech BNR Stock Holding History

T. Rowe Price Associates’s Portfolio BNR Stock Details BNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-32,636	Closed	-$734K	–	2929
2022 Q4	$734K	Sell	32,636 -1,290	-4%	-$29.4K	﹤0.01%	1946
2022 Q3	$811K	Buy	33,926 +971	+3%	+$31.3K	﹤0.01%	1866
2022 Q2	$959K	Sell	32,955 -2,181	-6%	-$97.4K	﹤0.01%	1918
2022 Q1	$3.26M	Sell	35,136 -24,186	-41%	-$2.1M	﹤0.01%	1554
2021 Q4	$5.65M	Buy	59,322 +3,874	+7%	+$531K	﹤0.01%	1481
2021 Q3	$9.91M	Sell	55,448 -285	-0.5%	-$63.4K	﹤0.01%	1417
2021 Q2	$16.4M	Sell	55,733 -16,734	-23%	-$4.95M	﹤0.01%	1345
2021 Q1	$19.5M	Sell	72,467 -13,636	-16%	-$4.15M	﹤0.01%	1280
2020 Q4	$19.9M	Buy	86,103 +10,734	+14%	+$2.88M	﹤0.01%	1229
2020 Q3	$18.9M	Sell	75,369 -3,521	-4%	-$834K	﹤0.01%	1171
2020 Q2	$21.3M	Buy	+78,890	New	+$21.6M	﹤0.01%	1128

Other funds holding BNR

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates's BNR Position: Q1 2023 in Review

T. Rowe Price Associates sold out of Burning Rock Biotech (BNR) in Q1 2023, closing a stake of 32,636 shares — an estimated $734K sold.

T. Rowe Price Associates first reported a position in BNR in Q2 2020 and held it in 11 quarters. The position peaked at $21.3M in Q2 2020. 34 funds tracked by Wall St. Rank hold BNR as of Q1 2023.

T. Rowe Price Associates reported no remaining Burning Rock Biotech position as of Q1 2023 after selling out during the quarter.
T. Rowe Price Associates sold 32,636 Burning Rock Biotech shares in Q1 2023, an estimated $734K.
T. Rowe Price Associates first reported a position in Burning Rock Biotech in Q2 2020 and held it in 11 quarters.
T. Rowe Price Associates's Burning Rock Biotech position peaked at $21.3M in Q2 2020.
34 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q1 2023.

Based on T. Rowe Price Associates's 13F filing for Q1 2023, filed 15 May 2023.